Delivery Order HHSO100201300006I-HHSO10033002T
Award Date 9/30/16
Potential Completion Date 9/29/21
Potential Value $38M
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Thousand Oaks, CA 91320, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Amgen USA Inc., a subsidiary of Amgen Inc., to provide a colony stimulating factor (G-CSF or GM-CSF) as a medical countermeasure for mitigating neutropenia arising from exposure to ionizing radiation. The contract is a $154,445,489.12 firm fixed price delivery order under the HHS Colony Stimulating Factor 2013-2018 indefinite delivery contract. The award...
- This firm fixed price delivery order was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response against the HHS Colony Stimulating Factor 2013-2018 master indefinite delivery indefinite quantity contract. Valued at $708,420.30, the order is for maintenance of previously purchased colony stimulating factor(s), specifically G- or GM-CSF, for mitigation of neutropenia arising from exposure to ionizing radiation. The products will be...
- This contract awarded to Amgen Inc. by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) provides $33,719,968.24 to advance the development of romiplostim for the treatment of hematopoietic subsyndrome-acute radiation syndrome (HS-ARS) and chemotherapy-induced thrombocytopenia (CIT), as well as a drug delivery device feasibility project. The contract includes a $3,711,014.00 supplement to CLIN 002 and the de-obligation of...
- This is a $45,162,200.00 definitive, firm-fixed price contract awarded to Coherus Biosciences, Inc. by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency. The contract is for PEGFILGRASTIM 6MG/.06ML (INJ, SOLN, SYR OR AUTOINJECTOR) and VMI, with a period of performance through March 18, 2030. The contract does not have a set-aside designation. As a provider of biopharmaceutical products, Coherus Biosciences, Inc. will deliver the specified injectable...
- This contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Amgen Inc., a for-profit manufacturer, to develop an NPLATE administration kit for the treatment of approved indications, including Acute Radiation Syndrome (ARS). The contract is a definitive, cost-sharing contract with a potential value of $7,290,923.50 and a completion date of August 27, 2026. The contract award is not associated with a set-aside...
- This federal contract award is for the pharmaceutical product Neupogen 480 mcg/0.8 mL syringe, awarded to the prime contractor Amerisourcebergen Drug Corp. The $2,482.88 firm fixed price delivery order has an ultimate completion date of November 22, 2024. The contract was awarded on November 21, 2024 by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency supplying medical products to military treatment facilities and veterans' healthcare programs. Amerisourcebergen, a...
- This federal contract award, with an ID of 75N91023D00010|75N91024F00001, was issued by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services. The contract, which is not set aside, has a ceiling value of $1,866,116.00 and a completion date of September 17, 2026. The scope of the contract includes the production of a drug substance, conversion of the drug substance to a drug product, filling the drug product into applicators for clinical...
- This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Macrogenics, Inc., a for-profit manufacturer, for research and development services related to advanced development. The contract has a ceiling value of $56,058,625.93 and was awarded on September 29, 2006, with an ultimate completion date of September 28, 2011. The contract is not set-aside for any...
- The Department of Defense's Medical Supply Chain has awarded a delivery order valued at $2,852.00 to AmerisourceBergen Drug Corp for Granix 480 mcg/0.8 ml in safe syringes. This competitive award, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,214.78 firm fixed-price delivery order is for the supply of NEUPOGEN 300 MCG/ML VIALML, a specialty pharmaceutical product, with a contract period ending on February 6, 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract...